FCGR3A and neoplasm: Recently, Woan et al. had been successfully produced a triple-gene-edited (expressing non-cleavable CD16 and IL15-RF, knocking out CD38) iPSC-NK cells that elicited strong anti-tumor activity in vivo (Woan et al. 2021).